These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 33784930)

  • 1. Lasmiditan efficacy in migraine attacks with mild vs. moderate or severe pain.
    Peres MFP; Vasudeva R; Baygani SK; Dennehy EB; Vincent M; Friedman DI
    Curr Med Res Opin; 2021 Jun; 37(6):1031-1038. PubMed ID: 33784930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
    Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
    Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of 2-Hour Post-Dose Efficacy of Lasmiditan for the Acute Treatment of Difficult-to-Treat Migraine Attacks.
    Tepper SJ; Vasudeva R; Krege JH; Rathmann SS; Doty E; Vargas BB; Magis D; Komori M
    Headache; 2020 Sep; 60(8):1601-1615. PubMed ID: 32634275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained responses to lasmiditan: Results from post-hoc analyses of two Phase 3 randomized clinical trials for acute treatment of migraine.
    Doty EG; Krege JH; Jin L; Raskin J; Halker Singh RB; Kalidas K
    Cephalalgia; 2019 Oct; 39(12):1569-1576. PubMed ID: 31266353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A close association of freedom from pain, migraine-related functional disability, and other outcomes: results of a post hoc analysis of randomized lasmiditan studies SAMURAI and SPARTAN.
    Lipton RB; Baygani SK; Tepper SJ; Krege JH; Vasudeva R; Pearlman EM; Hauck PM; Loo LS
    J Headache Pain; 2021 Aug; 22(1):101. PubMed ID: 34454420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
    Loo LS; Plato BM; Turner IM; Case MG; Raskin J; Dowsett SA; Krege JH
    BMC Neurol; 2019 Aug; 19(1):191. PubMed ID: 31409292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and Safety of Lasmiditan Treatment in Elderly Patients With Migraine: Post Hoc Analyses From Randomized Studies.
    Martin VT; Ahmed Z; Hochstetler HM; Baygani SK; Dong Y; Hauck PM; Khanna R
    Clin Ther; 2021 Jun; 43(6):1066-1078. PubMed ID: 34366152
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
    Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
    J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials.
    Doty EG; Hauck PM; Krege JH; Komori M; Hake AM; Dong Y; Lipton RB
    CNS Drugs; 2022 Jul; 36(7):771-783. PubMed ID: 35779194
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of Efficacy Following Oral Treatment With Lasmiditan for the Acute Treatment of Migraine: Integrated Results From 2 Randomized Double-Blind Placebo-Controlled Phase 3 Clinical Studies.
    Ashina M; Vasudeva R; Jin L; Lombard L; Gray E; Doty EG; Yunes-Medina L; Kinchen KS; Tassorelli C
    Headache; 2019 Nov; 59(10):1788-1801. PubMed ID: 31529622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials.
    Loo LS; Ailani J; Schim J; Baygani S; Hundemer HP; Port M; Krege JH
    J Headache Pain; 2019 Jul; 20(1):84. PubMed ID: 31340760
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
    Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
    Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study.
    Reuter U; Krege JH; Lombard L; Gomez Valderas E; Krikke-Workel J; Dell-Agnello G; Dowsett SA; Buse DC
    Cephalalgia; 2022 Jan; 42(1):20-30. PubMed ID: 34644189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lasmiditan in patients with common migraine comorbidities: a
    Clemow DB; Baygani SK; Hauck PM; Hultman CB
    Curr Med Res Opin; 2020 Nov; 36(11):1791-1806. PubMed ID: 32783644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
    Sakai F; Takeshima T; Homma G; Tanji Y; Katagiri H; Komori M
    Headache; 2021 May; 61(5):755-765. PubMed ID: 33990951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Migraine history and response to lasmiditan across racial and ethnic groups.
    Charleston L; Savage-Edwards B; Bragg SM; Baygani SK; Dennehy EB
    Curr Med Res Opin; 2022 May; 38(5):721-730. PubMed ID: 35350937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety findings from Phase 3 lasmiditan studies for acute treatment of migraine: Results from SAMURAI and SPARTAN.
    Krege JH; Rizzoli PB; Liffick E; Doty EG; Dowsett SA; Wang J; Buchanan AS
    Cephalalgia; 2019 Jul; 39(8):957-966. PubMed ID: 31166697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lasmiditan for the acute treatment of migraine: Subgroup analyses by prior response to triptans.
    Knievel K; Buchanan AS; Lombard L; Baygani S; Raskin J; Krege JH; Loo LS; Komori M; Tobin J
    Cephalalgia; 2020 Jan; 40(1):19-27. PubMed ID: 31744319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Dizziness After Lasmiditan Usage: Findings From the SAMURAI and SPARTAN Acute Migraine Treatment Randomized Trials.
    Tepper SJ; Krege JH; Lombard L; Asafu-Adjei JK; Dowsett SA; Raskin J; Buchanan AS; Friedman DI
    Headache; 2019 Jul; 59(7):1052-1062. PubMed ID: 31152441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine.
    Goadsby PJ; Wietecha LA; Dennehy EB; Kuca B; Case MG; Aurora SK; Gaul C
    Brain; 2019 Jul; 142(7):1894-1904. PubMed ID: 31132795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.